DOCSLIB.ORG

Rapid Control of Severe Neoplastic Hypercortisolism with Metyrapone and Ketoconazole

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rapid Control of Severe Neoplastic Hypercortisolism with Metyrapone and Ketoconazole J-B Corcuff, J Young and Rapid control of severe 172:4 473–481 Clinical Study others hypercortisolism Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole Jean-Benoıˆt Corcuff*, Jacques Young1,*, Pauline Masquefa-Giraud2, Philippe Chanson1, Eric Baudin3 and Antoine Tabarin2 Department of Nuclear Medicine, Haut Le´ veˆ que Hospital, F-33604 Pessac, France, 1Department of Endocrinology, Correspondence Biceˆ tre Hospital, F-94275 Le Kremlin-Biceˆ tre, France, 2Department of Endocrinology, Haut Le´ veˆ que Hospital, should be addressed CHU Bordeaux, F-33604 Pessac, France and 3Department of Nuclear Medicine and Oncology, Gustave Roussy, to A Tabarin F-94800 Villejuif, France Email *(J-B Corcuff and J Young contributed equally to this work) antoine.tabarin@ chu-bordeaux.fr Abstract Context: Severe Cushing’s syndrome elicited by ectopic ACTH syndrome (EAS) or adrenal carcinoma (ACC) can threaten life in the short term. The effectiveness of oral administration of the inhibitors of steroidogenesis ketoconazole and metyrapone in this situation is poorly described. Objective: To report the short-term effectiveness and tolerability of metyrapone and ketoconazole elicited either by EAS or by ACC in patients exhibiting severe hypercortisolism. Design: Retrospective analysis of data obtained for patients with urinary free cortisol (UFC) level estimated to be fivefold the upper limit of the normal range (ULN). Patients and settings: A total of 14 patients with EAS and eight with ACC treated in two tertiary-care university hospitals. Intervention: Metyrapone and ketoconazole treatment in combination (along with symptomatic treatments for co-morbidities). European Journal of Endocrinology Main outcome: Evolution of clinically relevant endpoints (blood pressure, kalaemia and glycaemia) and biological intensity of hypercortisolism 1 week and 1 month after starting steroidogenesis inhibition. Results: After 1 week of treatment, median UFC fell from 40.0 to 3.2 ULN and from 16.0 to 1.0 ULN in patients with EAS and ACC respectively. Median UFC after 1 month of treatment was 0.5 and 1.0 ULN in patients with EAS and ACC respectively and UFC values were normal in 73 and 86% of patients respectively. Clinical status improved dramatically along with kalaemia, glycaemia and blood pressure, allowing a decrease in the relevant treatments. Side effects were minimal and only two patients (one EAS and one ACC) experienced plasma transaminase elevations necessitating ketoconazole withdrawal. Conclusion: Metyrapone–ketoconazole combination therapy is well tolerated and provides rapid control of endocrine cancer-related life-threatening hypercortisolism. European Journal of Endocrinology (2015) 172, 473–481 Introduction Untreated or inadequately treated Cushing’s syndrome and infections. During severe CS as observed in patients (CS) is a morbid condition leading to numerous compli- with underlying neuroendocrine neoplasms responsible cations. The latter ultimately results in an increased for ectopic adrenocorticotrophin (ACTH) syndrome (EAS) mortality that is mainly due to cardiovascular events and in those with adrenal carcinomas (ACCs) (1), www.eje-online.org Ñ 2015 European Society of Endocrinology Published by Bioscientifica Ltd. DOI: 10.1530/EJE-14-0913 Printed in Great Britain Downloaded from Bioscientifica.com at 09/30/2021 09:32:09AM via free access Clinical Study J-B Corcuff, J Young and Rapid control of severe 172:4 474 others hypercortisolism the catabolic and metabolic consequences of CS are The aim of this study was to analyse the short-term exacerbated including severe hypertension, hypokalaemia, clinical and biological effectiveness and tolerability of the major hyperglycaemia and bedridden condition secondary metyrapone and ketoconazole in a significant number of to amyotrophia (2, 3, 4, 5, 6). Severe hypercortisolism also patients with severe hypercortisolism due to EAS or ACC. favours systemic infection, sepsis due to opportunistic pathogens such as Pneumocystis carinii (7) and venous thromboembolism (8). Patients with severe hypercortiso- Patients and methods lism may experience other complications such as acute Patients heart and respiratory failure, peritonitis due to gut perforation, pancreatitis and acute psychosis. In such Data for 22 patients treated in the endocrinology instances, curative surgery of the source of ACTH secretion departments of Biceˆtre and Bordeaux university hospitals or of the ACC may be impossible to perform and cytotoxic (France) were analysed. The data were collected as part of chemotherapy may be associated with an increased risk of routine patient management, and local ethics committee infections and death (9). Essentially, severe hypercortiso- approval was obtained for their analysis. Patients were lism threatens the short-term vital prognosis, pulmonary eligible for the study if they had poor clinical status due embolism and infections being significant causes of death to severe hypercortisolism related to underlying EAS or in patients with EAS (10, 11, 12). Surgical removal of the ACC. Severe hypercortisolism was defined as a mean 24-h neoplasm responsible for CS is not always possible, either urinary free cortisol (UFC) level O5 times the upper limit because ectopic ACTH-secreting tumours may be occult of the normal range (ULN) in at least three samples. at symptom onset or because ectopic ACTH-secreting Fourteen patients (12M/2F; age 53 (24–71) years) had tumours and ACCs are unresectable or metastasised. EAS. The ACTH-secreting tumours were: bronchial (# 1, 2, 6 Bilateral adrenalectomy (BLA) may be an option in patients and 11) or pancreatic (# 5, 7, 10 and 12) or thymic carcinoid with EAS, but pre-operative control of hypercortisolism tumours (# 13), of unknown origin (metastatic neuro- may facilitate surgery and avoid perioperative compli- endocrine carcinoma, # 8), small-cell lung carcinomas cations in patients with poor overall condition (13). (# 3 and 9), medullary thyroid carcinoma (# 14), and one Otherwise, rapid correction of hypercortisolism is occult tumour (# 4). Eight patients had cortisol-secreting recommended before induction of cytotoxic chemother- ACC (2M/6F; age 60 (20–71) years). The ENSAT stages (20) apy in order to minimise the side effects of myelosuppres- were 2 and 4 in three and five patients respectively. sive cytotoxic chemotherapy (14). Thus, rapid control of Complications of hypercortisolism aregiven in Tables 1 European Journal of Endocrinology hypercortisolism is mandatory to ensure short-term survi- and 2. Briefly, 96% of patients were hypertensive, val and enable medical or surgical therapies directed at the 88% had hypokalaemia and 75% developed diabetes. underlying tumour. Yet, very few studies have addressed In addition, half of the patients had at least one other this issue. Glucocorticoid receptor blockade with mife- severe complication due to severe CS (psychiatric dis- pristone has occasionally been reported to be effective (15) orders, opportunistic infections, phlebitis or pulmonary but is difficult to monitor and may worsen pre-existing embolism, fractures, bedsores and bedridden status due to hypertension and hypokalaemia. Inhibition of steroido- sarcopenia). genesis with the anaesthetic drug etomidate has also been reported but its hypnotic properties limit its use (16). Intervention Metyrapone and ketoconazole are fast-acting, orally administered drugs that inhibit distinct enzymes involved All the patients received oral combination therapy with in adrenal steroidogenesis and thereby reduce cortisol metyrapone (Metopirone 250 mg; Novartis) and ketoco- production synergistically (2, 17, 18, 19). There are few nazole (Nizoral 200 mg; Janssen-Cilag, Issy-les-Mouli- published data on the treatment of severe hypercortiso- neaux, France). Metyrapone and ketoconazole were lism with these two drugs, alone or in combination, and introduced either simultaneously or sequentially in the this is especially true for patients with ACC. In addition, time frame of the study. Mitotane (Lysodren 500 mg; the rare published series and case reports often lack HRA-Pharma, Paris, France) was also introduced simul- detailed information about the impact of these drugs on taneously or later in six out of 14 patients with EAS and six the magnitude of the biological response and the impact out of eight patients with ACC. The starting dosages were on hypercortisolism-induced morbidities such as hyper- variable (median: metyrapone 2125 mg/day and ketoco- tension, hypokalaemia and hyperglycaemia (4, 10, 11). nazole 900 mg/day) and were subsequently adjusted www.eje-online.org Downloaded from Bioscientifica.com at 09/30/2021 09:32:09AM via free access Clinical Study J-B Corcuff, J Young and Rapid control of severe 172:4 475 others hypercortisolism Table 1 Clinical and dosage levels of patients with ectopic ACTH syndrome and adrenal carcinomas. Ketoconazole dosage Metyrapone dosage Lysodren dosage BMI Age Low No. Tumour Sex (kg/m2) (years) HT KC DM T0 W1 M1 T0 W1 M1 T0 W1 M1 1 BCa M 25.8 23.9 Yes Yes Yes 1000 1000 1000 1000 1000 2000 0 0 0 2 BCa M 24.3 28.5 No Yes No 1000 1000 1000 1000 1000 1000 0 0 0 3 SCLC M 26.6 57.5 Yes Yes Yes 1200 1200 – 3000 3000 – 3000 3000 – 4 Unk M 28.0 51.7 Yes Yes Yes 1000 1000 1000 3000 3000 3000 3000 3000 3000 5 PCa F 22.7 39.6 Yes Yes Yes 800 800 800 1500 1500 1500 0 0 0 6 BCa M 30.0 35.1 Yes No Yes 800 800 800 500 500 500 0 0 0 7 PCa M 35.3 53.8 Yes Yes Yes 1000 0 0 1500 1500 2250 0 0 4000 8 NET M 60.2 Yes Yes Yes 1000 1200 1200
Load more

Recommended publications
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • Ketoconazole (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Ketoconazole (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada APO-Ketoconazole; Ketoconazole-200; TEVA-Ketoconazole Warning This drug is not for use to treat certain types of fungal infections. This includes fungal infections of the skin, nails, or brain. Talk with the doctor. This drug must only be used when other drugs cannot be used or have not worked. Talk with your doctor to be sure that the benefits of this drug are more than the risks. Very bad and sometimes deadly liver problems like the need for a liver transplant have happened with this drug. Some people did not have a raised chance of liver problems before taking this drug. Most of the time, but not always, liver problems have gone back to normal after this drug was stopped. Call your doctor right away if you have signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes. Blood tests will be needed to watch for any liver problems. Talk with your doctor. Taking this drug with certain other drugs may raise the chance of very bad and sometimes deadly heart problems like a heartbeat that is not normal. Do not take this drug if you are taking any of these drugs: Cisapride, disopyramide, dofetilide, dronedarone, methadone, pimozide, quinidine, or ranolazine. Ketoconazole (Systemic) 1/6 What is this drug used for? It is used to treat fungal infections.
    [Show full text]
  • Treatment of Peripheral Precocious Puberty
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks Treatment of Peripheral Precocious Puberty Melissa Schoelwer, MD and Erica A Eugster, MD Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana Send correspondence to: 705 Riley Hospital Drive, Room 5960 Indianapolis, IN 46202 Phone: 317-944-3889 Fax: 317-944-3882 Email: [email protected] __________________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schoelwer, M., & Eugster, E. A. (2016). Treatment of Peripheral Precocious Puberty. In Puberty from Bench to Clinic (Vol. 29, pp. 230-239). Karger Publishers. http://dx.doi.org/10.1159/000438895 Peripheral Precocious Puberty Abstract There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and Familial Male-Limited Precocious Puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.
    [Show full text]
  • CYP3A4 Mediated Pharmacokinetics Drug Interaction Potential of Maha
    www.nature.com/scientificreports OPEN CYP3A4 mediated pharmacokinetics drug interaction potential of Maha‑Yogaraj Gugglu and E, Z guggulsterone Sarvesh Sabarathinam1, Satish Kumar Rajappan Chandra2 & Vijayakumar Thangavel Mahalingam1* Maha yogaraja guggulu (MYG) is a classical herbomineral polyherbal formulation being widely used since centuries. The aim of this study was to investigate the efect of MYG formulation and its major constituents E & Z guggulsterone on CYP3A4 mediated metabolism. In vitro inhibition of MYG and Guggulsterone isomers on CYP3A4 was evaluated by high throughput fuorometric assay. Eighteen Adult male Sprague–Dawley rats (200 ± 25 g body weight) were randomly divided into three groups. Group A, Group B and Group C were treated with placebo, MYG and Standard E & Z guggulsterone for 14 days respectively by oral route. On 15th day, midazolam (5 mg/kg) was administered orally to all rats in each group. Blood samples (0.3 mL) were collected from the retro orbital vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 12 and 24 h of each rat were collected. The fndings from the in vitro & in vivo study proposed that the MYG tablets and its guggulsterone isomers have drug interaction potential when consumed along with conventional drugs which are CYP3A4 substrates. In vivo pharmacokinetic drug interaction study of midazolam pointed out that the MYG tablets and guggulsterone isomers showed an inhibitory activity towards CYP3A4 which may have leads to clinically signifcant interactions. Te use of alternative medicine such as herbal medicines, phytonutrients, ayurvedic products and nutraceuticals used widely by the majority of the patients for their primary healthcare needs.
    [Show full text]
  • PROCUR Why Procur Has Been Prescribed for You
    Consumer Medicine Information Ask your doctor if you have any questions about PROCUR why Procur has been prescribed for you. Cyproterone acetate 50 mg and 100 mg tablets This medicine is available only with a doctor's prescription. What is in this leaflet Before you take Procur Please read this leaflet carefully before you start taking Procur When you must not take it This leaflet answers some common questions about Procur. It does not contain all the available Do not take Procur if you have an allergy to: information. It does not take the place of talking • any medicine containing cyproterone acetate to your doctor or pharmacist. • any of the ingredients listed at the end of this leaflet All medicines have risks and benefits. Your doctor has weighed the risks of you taking Procur against Some of the symptoms of an allergic reaction may the benefits they expect it will have for you. include: • difficulty in breathing or wheezing If you have any concerns about taking this • shortness of breath medicine, ask your doctor or pharmacist. • swelling of the face, tongue, lips, or other parts of the body Keep this leaflet with the medicine. You may • hives on the skin, rash, or itching need to read it again. Do not take Procur if: What Procur is used for • you are allergic to cyproterone acetate or any other ingredient listed at the end of this leaflet Procur tablets contain the active ingredient • you are pregnant cyproterone acetate. Cyproterone acetate is an • you are breastfeeding antiandrogen. It works by blocking the actions of • you suffer from liver diseases (including sex hormones (androgens) that are produced previous or existing liver tumours, Dubin- mainly in men but also, to a lesser extent in Johnson syndrome or Rotor syndrome) women.
    [Show full text]
  • Studies on the Interactions Between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol
    1844 Biol. Pharm. Bull. 27(11) 1844—1849 (2004) Vol. 27, No. 11 Studies on the Interactions between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol a b,1) b b, c Takashi SATOH, Yuki TOMIKAWA, Kaori TAKANASHI, Shinji ITOH, * Shungo ITOH, and b Itsuo YOSHIZAWA a Yakuhan Pharmaceutical Co., Ltd.; Kitahiroshima, Hokkaido 061–1111, Japan: b Hokkaido College of Pharmacy; Otaru, Hokkaido 047–0264, Japan: and c Japan Seamen-Relief-Association Otaru Hospital; 1–7–10 Ironai, Otaru, Hokkaido 047–0031, Japan. Received July 5, 2004; accepted August 27, 2004 To determine the inhibition effects of drugs on the glucuronidation of estradiol (E2), 29 drugs that have been reported to induce gynecomastia were examined in the presence of UDP-glucuronic acid using human hepatic microsomes (pooled) as the enzyme source. The percentage inhibition of the E2 glucuronidation was determined at drug concentrations of 1 mM (approximate therapeutic concentration) and 100 mM (non-clinical overdose con- centration) based on the rate constants for the 3- and 17-glucuronidation of E2 (11.2 and 2.52 pmol/min/mg pro- tein, respectively). The only drug that exhibited 50% or higher inhibition of the 3-glucuronidation at a concen- tration of 1 mM was manidipine (54.4%). When the concentration was 100 mM, manidipine exhibited 100% inhibi- tion of the 3-glucuronidation, and other drugs that exhibited 50% or higher inhibition of the 3-glucuronidation were nicardipine (92%), nisoldipine (90%), nifedipine (84%), domperidone (81%), tacrolimus (80%), nitrendip- ine (77%) and ketoconazole (69%).
    [Show full text]
  • Systemic Effect of Inhaled Corticosteroids on Adrenal
    Issa-El-Khoury et al. Allergy, Asthma & Clinical Immunology (2015) 11:9 DOI 10.1186/s13223-015-0075-z ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY POSITION ARTICLE AND GUIDELINES Open Access CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma Karine Issa-El-Khoury1, Harold Kim2,3, Edmond S Chan4, Tim Vander Leek5 and Francisco Noya1* Abstract Asthma is a chronic inflammatory disease of the airways that affects a growing number of children and adolescents. Inhaled corticosteroids (ICS) are the mainstay of treatment in persistent asthma, with a stepwise approach to increasing doses of ICS depending on asthma severity and control. ICS have known local and systemic side effects, of which adrenal suppression is still under-recognized. The latter is associated with chronic exposure and higher doses, although it has rarely been reported in children receiving low doses for a short period of time. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recommends that physicians screen for adrenal suppression in children receiving high doses for more than 6 months and to consider screening those on medium dose if the risk is deemed higher by factors that increase an individual’s systemic corticosteroid exposure. Morning serum cortisol level can be used as a screening tool and abnormal results or normal results with a high index of suspicion should be confirmed with low-dose ACTH stimulation tests. Keywords: Asthma, Inhaled corticosteroids, Fluticasone, Adrenal suppression Background reducing asthma mortality. Most patients can achieve Asthma affects about 10% of the Canadian population, and asthma control using relatively low doses of ICS, which 50-80% of children affected develop it before the age of 5 will produce maximum or near-maximum clinical benefit, years [1].
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • KETOCONAZOLE Your Dosage Is: Ketoconazole Can Increase Liver Enzymes
    Your dosage is: KETOCONAZOLE Ketoconazole can increase liver enzymes . 200 mg tablet This usually does not give any symptoms. Other names: Nizoral Rarely, hepatitis (an inflammation of the ____tablet(s) (____mg) ____time(s) a day liver) can occur. Signs of this are yellowing WHY is this drug prescribed? of the eyes and skin, dark urine, fever, or nausea and / or vomiting, pale stools, Ketoconazole is an antifungal drug. It is fatigue, and abdominal pain. Call your used to treat fungal infections in the mouth 20 mg / mL oral suspension doctor or pharmacist if these symptoms (like thrush), the esophagus, the genital occur. tract (like a yeast infection) and other areas. ____mL (____mg) ____ time(s) a day The drug may also be used to prevent a Other rare adverse effects that may occur relapse after treatment of the initial infection. Shake well before each use include lowering of white blood cells (cells that fight infections), and lowering of HOW should this drug be taken? Take ketoconazole for the duration of time it platelets (needed to help your blood clot). is prescribed. If you stop it earlier, your Inform your doctor if you notice any Ketoconazole is available in 200 mg tablets infection may come back. If the infection symptoms of fever, chills, bleeding or and a 20 mg/mL oral suspension. worsens or persists, consult your doctor. bruising. The dose of ketoconazole will depend on the What should you do if you FORGET a Your doctor will do regular blood tests to type of infection that is being treated. It is dose? verify your liver and adrenal gland function usually given once daily.
    [Show full text]
  • What's the Best Treatment for Cradle Cap?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ryan C. Sheffield, MD, Paul Crawford, MD What’s the best treatment Eglin Air Force Base Family Medicine Residency, Eglin Air for cradle cap? Force Base, Fla Sarah Towner Wright, MLS University of North Carolina at Chapel Hill Evidence-based answer Ketoconazole (Nizoral) shampoo appears corticosteroids to severe cases because to be a safe and efficacious treatment of possible systemic absorption (SOR: C). for infants with cradle cap (strength of Overnight application of emollients followed recommendation [SOR]: C, consensus, by gentle brushing and washing with usual practice, opinion, disease-oriented baby shampoo helps to remove the scale evidence, and case series). Limit topical associated with cradle cap (SOR: C). ® Dowden Health Media Clinical commentary ICopyrightf parents can’t leave it be, recommend brush to loosen the scale. Although mineral oil andFor a brush personal to loosen scale use noonly evidence supports this, it seems safe Cradle cap is distressing to parents. They and is somewhat effective. want everyone else to see how gorgeous This review makes me feel more FAST TRACK their new baby is, and cradle cap can make comfortable with recommending ketocon- their beautiful little one look scruffy. My azole shampoo when mineral oil proves If parents need standard therapy has been to stress to the insufficient. For resistant cases, a cute hat to do something, parents that it isn’t a problem for the baby. can work wonders. If the parents still want to do something
    [Show full text]
  • Auspar Attachment 1: Product Information for Progesterone
    Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> AUSTRALIAN PRODUCT INFORMATION – ORIPRO® (PROGESTERONE) PESSARIES 1 NAME OF THE MEDICINE Progesterone 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Oripro Pessaries contain as active substance 100mg or 200mg of progesterone (micronized) in hard fat. 3 PHARMACEUTICAL FORM Vaginal Pessaries - Opaque, bullet-shaped waxy, solid masses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oripro Pessaries are indicated for: 1. Assisted reproductive technology (ART) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy. 2. Prevention of preterm birth in singleton pregnancies at risk due to; · Shortened cervix 1 Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> The dosage of progesterone for prevention of preterm birth is 200 mg daily (at night). Treatment can be initiated during the second trimester (16-24 weeks gestation) and is to be continued to the end of the 36th week of gestation or until delivery.
    [Show full text]